||Molecular mechanisms underlying opioid tolerance.
||Professor Graeme Henderson, University of Bristol
||Gene-deletion of prostanoid receptors will improve our knowledge of disease processes and lead to clinically useful drugs.
||Professor Robert Jones, University of Strathclyde
||Do endogenous biolipids have a role in regenerative medicine?
||Professor Anwar R Baydoun, University of Hertfordshire
||How could biomarkers be exploited in understanding and/or managing vascular calcification?Professor Anwar R Baydoun, University of Hertfordshire
||Cationic amino acid transporters as novel targets for therapeutic intervention in cardiovascular diseases.
||Evaluation of the evidence that MDMA ('ecstasy') produces neurotoxic damage in the human brain.
||Professor A. Richard Green, University of Nottingham
||Molecular determinants of ion channel conduction in Cys-loop receptors.
||Professor John Peters, University of Dundee
||Safe limits for driving when taking medication.
||Dr Paul Skett, University of Glasgow
||Heroin - a dangerous drug?
||Understanding ligand bias and its potential for pharmacological and therapeutic advantage.
||Professor R.A. John Challiss, University of Leicester
||Nitric oxide-independent/heme-independent soluble guanylyl cyclase activators: molecular mechanism of action and therapeutic potential.
||Professor Andreas Papapetropoulos, University of Patras, Greece
||Therapeutic opportunities for gasotransmitters and gasotransmitter-inhibitor drugs.
||Agents (approved from human use or in development) that target vascular endothelial growth factor: mechanisms of action and therapeutic applications.
||Lifestyle drugs and their impact on society.
||Professor Rod Flower, The William Harvey Research Institute, Queen Mary, University of London
||Formyl peptide receptor biology.
||Professor Mauro Perretti, The William Harvey Research Institute, Queen Mary, University of London
||Anti-thrombotics that target the platelet; what old and new drugs might we be using in ten years' time?
||Professor Tim Warner, The William Harvey Research Institute, Queen Mary, University of London
||Novel corticosteroid therapeutics - what does the future hold?
||Professor Nick Goulding, The William Harvey Research Institute, Queen Mary, University of London
||Discuss the therapeutic potential of inorganic nitrite/nitrate based therapy.
||Professor Amrita Ahluwalia, The William Harvey Research Institute, Queen Mary, University of London
||Therapeutic potential of female sex hormones in treatment of cardiovascular diseases.
||Dr Ramona Scotland, The William Harvey Research Institute, Queen Mary, University of London
||Describe how amino acids and their analogues/ derivatives are used as drugs: include a description of potential novel therapeutic uses and short peptide sequences where the activity relates mainly to a single amino acid.
||Dr Andy Webb, King’s College London
||Is inflammation good or bad?
||Dr Derek Gilroy, University College London
||Despite the rigours of drug development, why do some drugs still fail at the ultimate step (the RCT)?
||Dr Aroon Hingorani, University College London
||Discuss the therapeutic potential of NOS inhibitors.
||Professor Adrian Hobbs, Barts and The London School of Medicine and Dentistry at Queen Mary, University of London
||Aspirin - the new wonder drug: As an analgesic aspirin is associated with significant side effects; however in recent years several new indications for aspirin have started to emerge - critically review the evidence for these alternative uses of aspirin.
||Dr Fiona Dowell, University of Glasgow Veterinary School
||The future of pharmacological treatments in veterinary medicine is pharmacogenetics - discuss.
||Can fluorescent receptor ligands and transporter substrates be used to efficiently and safely screen for new drugs?
|Dr Keith Brain, University of Birmingham
||Targeting the vicious cycle of cancer-induced bone disease.
||Dr Claire M. Edwards, University of Oxford
||An insight into the relationship between inflammation and cancer and COX-2 as a potential target in colon cancer therapy.
||Dr Naeem Mubarak, Hamdard University, Pakistan
||Current and novel therapies for acute kidney injury.
||Jill Darton, GlaxoSmithKline, UK